These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Sokal EM, Antunes H, Beguin C, Bodeus M, Wallemacq P, de Ville de Goyet J, Reding R, Janssen M, Buts JP, Otte JB. Transplantation; 1997 Nov 27; 64(10):1438-42. PubMed ID: 9392308 [Abstract] [Full Text] [Related]
13. Association between liver transplantation for Langerhans cell histiocytosis, rejection, and development of posttransplant lymphoproliferative disease in children. Newell KA, Alonso EM, Kelly SM, Rubin CM, Thistlethwaite JR, Whitington PF. J Pediatr; 1997 Jul 27; 131(1 Pt 1):98-104. PubMed ID: 9255199 [Abstract] [Full Text] [Related]
19. Posttransplant lymphoproliferative disorders and gastrointestinal manifestations of Epstein-Barr virus infection in children following liver transplantation. Cao S, Cox K, Esquivel CO, Berquist W, Concepcion W, Ojogho O, Monge H, Krams S, Martinez O, So S. Transplantation; 1998 Oct 15; 66(7):851-6. PubMed ID: 9798693 [Abstract] [Full Text] [Related]